Paper
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma

https://doi.org/10.1016/0959-8049(92)90012-QGet rights and content

Abstract

Between February 1990 and April 1991, 59 previously untreated patients with progressive and/or symptomatic metastatic colorectal carcinoma were enrolled in a phase II study of 5-fluorouracil (5-FU) and interferon alfa-2b (IFN-α). 5-FU 750 mg/m2/day was administered as continuous infusion for 5 days, then weekly in a dose of 750 mg/m2 as intravenous push injection starting on day 15. IFN-α 9 MU was given subcutaneously three times a week. Treatment was given for a maximum of 6 months. 55 patients are evaluable for response and 51 for toxicity. 17 patients (31%) achieved a partial remission, 15 (27%) had stable disease and 21 patients (38%) had progressive disease. Median duration of remission was 5 months and median survival for all patients 10 months. Toxicity was important with two treatment-related deaths and severe leukopenia, fever, diarrhoea and mucositis in about one third of the patients. In our opinion, this regimen is effective but rather toxic in metastatic colorectal carcinoma.

References (16)

  • S Wadler et al.

    Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

    J Clin Oncol

    (1989)
  • S Wadler et al.

    Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma

    Sem Oncol

    (1990)
  • AB Miller et al.

    Reporting results of cancer treatment

    Cancer

    (1981)
  • R Pazdur et al.

    Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

    J Clin Oncol

    (1990)
  • N Kemeny et al.

    Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma: assessment of activity and toxicity

    Cancer

    (1990)
  • JY Douillard et al.

    Phase II trial of 5 fluourouracil (5 FU) and recombinant alpha interferon (R alpha-IFN) (Intron AR) in metastatic, previously untreated colorectal cancer (CRC)

    ASCO

    (1991)
  • M Huberman et al.

    Phase II trial of 5 fluorouracil (5 FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancer

    ASCO

    (1991)
  • S Wadler et al.

    Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an eastern cooperative oncology group study

    J Clin Oncol

    (1991)
There are more references available in the full text version of this article.

Cited by (15)

View all citing articles on Scopus
View full text